What the STRIDE Study Tells Us About Semaglutide and Weight Loss

What STRIDE actually measured, and why it was different from STEP 1

Most people searching for semaglutide trial data will land on the STEP 1 trial, which was the pivotal registration study showing around 15% average body-weight reduction over 68 weeks with semaglutide 2.4mg. STRIDE asked a different question. Its primary endpoint was six-minute walk distance: how far could participants walk in six minutes at baseline versus after treatment? That is a recognised, validated measure of cardiorespiratory fitness and functional capacity used widely in clinical research, particularly in populations where weight-related conditions affect mobility.

The trial enrolled adults living with obesity and either knee osteoarthritis or cardiovascular disease risk factors, people for whom the physical consequences of excess weight were already visible day to day. Semaglutide 2.4mg produced a statistically significant improvement in six-minute walk distance compared with placebo. Participants also lost a meaningful proportion of body weight, consistent with the STEP programme, but the functional improvement was tracked separately as its own outcome. Importantly, the trial attempted to distinguish how much of the fitness gain came from weight reduction alone versus a more direct effect of the medicine on muscle and metabolic function.

Lean-mass preservation was a secondary concern. Earlier research had raised the question of whether rapid weight loss on GLP-1 medicines might reduce muscle alongside fat. STRIDE contributed data on this, though interpreting lean-mass findings in the context of walking-capacity improvement is an area where more research is ongoing. The broader Wegovy weight-loss study evidence is worth reading alongside STRIDE for the full picture. NHS guidance on semaglutide covers the established clinical profile.

STRIDE alongside STEP and SELECT: building a fuller picture of semaglutide's effects

No single trial defines a medicine. Semaglutide's evidence base has been assembled across several major programmes, each answering a different question. STEP 1 established weight-loss efficacy. The SELECT trial then showed that semaglutide 2.4mg reduced the risk of major cardiovascular events (heart attack, stroke and cardiovascular death) in adults with pre-existing cardiovascular disease and overweight or obesity but without diabetes. That SELECT finding was significant enough that Wegovy received a UK licence extension covering cardiovascular risk reduction. STRIDE adds functional capacity to the list of outcomes studied.

Reading these trials together, a picture forms of a medicine that reduces body weight substantially, may lower serious heart-event risk in the right patients, and now appears to improve physical function. That last point is clinically meaningful for people whose quality of life is limited by how far or how comfortably they can move. It is also the kind of evidence that informs NICE appraisals and NHS commissioning decisions over time, the NICE appraisal of semaglutide for weight management (TA875) considered the evidence available at the time and sets out the conditions under which Wegovy is recommended on the NHS.

What none of the trials decide is whether semaglutide is right for a specific person. That requires a proper clinical assessment: medical history, current medicines, BMI, and any relevant conditions. Our prescribers work through exactly that when someone starts a consultation with semaglutide treatment through nume.

What STRIDE means in practice for people considering Wegovy

For most people weighing up treatment, the STRIDE findings are reassuring rather than decision-altering. They suggest that the benefits of semaglutide extend beyond what the scales show: that treatment may support the kind of physical capability that makes daily life feel easier, climbing stairs without stopping, walking to the bus, keeping up with the kids at the weekend. That is not a trivial outcome.

It also addresses a concern that sometimes circulates online about GLP-1 medicines and muscle loss. STRIDE's data do not suggest a straightforward trade of muscle for fat; the picture is more nuanced, and researchers are still refining their understanding. If lean mass and physical function matter specifically to you (as they reasonably should) that is worth raising at your consultation, not as a barrier but as a factor to discuss with a clinician who knows your full picture.

On the question of cost, understanding what you are paying for across different providers matters, our Wegovy pricing page explains what a legitimate private prescription includes. A quick note on process: the 12pm cut-off for same-day dispatch is a practical reality worth knowing before you order. Once a prescriber has reviewed and approved your consultation, medicine leaves our GPhC-registered pharmacy that afternoon with DPD and arrives the next working day, in plain packaging. Our clinical team can answer questions about the evidence, your eligibility, or anything else before you commit to anything.